Consequently, we retrospectively analyzed 205 PTCL patients, and aimed to study the significance of IL-10 in their treatment response, survival rate, and early relapse. This evidence concerns the gene IL10 and mature T-cell and NK-cell non-Hodgkin lymphoma.